Prihlásiť sa Zaregistrujte sa zadarmo

Dlh / vlastný kapitál spoločnosti ProMIS Neurosciences

Aká je hodnota metriky Dlh / vlastný kapitál spoločnosti ProMIS Neurosciences?

Hodnota metriky Dlh / vlastný kapitál spoločnosti ProMIS Neurosciences, Inc. je 2.63

Aká je definícia metriky Dlh / vlastný kapitál?



Dlh / vlastný kapitál (Debt to equity ratio) ukazovateľ vyjadruje pomer vlastného kapitálu a cudzích zdrojov na financovanie majetku spoločnosti.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Dlh / vlastný kapitál spoločností v sektore Health Care sektor na TSX v porovnaní so spoločnosťou ProMIS Neurosciences

Čomu sa venuje spoločnosť ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Firmy s metrikou dlh / vlastný kapitál podobnou spoločnosti ProMIS Neurosciences